Prof. Dr. Yeşim Eralp
Est-ce votre profil ? Revendiquez-le et vérifiez vos informations.
Revendiquer le profilPersonne ↔ Maladie
Sur quelles maladies ce médecin travaille-t-il ?
-
Tumeurs du sein 25 publicationsSource : OpenAlex / PubMed MeSHVoir les publications
- Tumeurs de l’ovaire 16 publications
- Tumeurs du poumon 13 publications
- Carcinome canalaire du sein 6 publications
- Carcinome pulmonaire non à petites cellules 6 publications
- Carcinome 4 publications
- Tumeurs glandulaires et épithéliales 3 publications
- Tumeurs du cerveau 3 publications
- Lymphome non hodgkinien 3 publications
- Adénocarcinome 3 publications
- Tumeurs osseuses 2 publications
- Carcinome lobulaire 2 publications
- Carcinome épithélial de l’ovaire 2 publications
- Thymome 2 publications
- Tumeurs du thymus 2 publications
- Tumeurs 2 publications
- Sarcome 2 publications
- Carcinome épidermoïde 2 publications
- Cystadenocarcinoma, Papillary 2 publications
- Adénocarcinome à cellules claires 2 publications
- Carcinome endométrioïde 2 publications
- Cystadénocarcinome séreux 2 publications
- Tumeurs du col de l’utérus 2 publications
- Tumeurs de l’œsophage 2 publications
- Balanitis 2 publications
Personne ↔ Maladie
Sur quels sujets ce médecin travaille-t-il ?
Domaines d’intérêt médical indiqués par le médecin lui-même sur sa page du site de l’établissement. Source : acibadem.com.tr.
- Ağız Kanseri
- Baş Boyun Kanserleri
- Beyin Tümörleri
- Böbrek Kanseri
- Böbrek Üstü Bezi Kanseri
- Akciğer, Akciğer Zarı Kanserleri (Mezotelyoma) ve Diğer Torasik Kanserler
- Dil ve Dil Kökü Kanseri
- Anal (Makat) Kanseri
- Burun İçi Tümörleri
- Malign Melanom ve Diğer Deri Tümörleri
- Akciğer Kanseri
- Dil Kanseri
CV
Formation et expérience
Expérience
- 2019Acıbadem Sağlık Grubuacibadem.com.tr
- 2018 - 2019İstanbul Florence Nightİngale Hastanesi / Tıbbi Onkoloji Uzmanıacibadem.com.tr
- 2010 - 2018İstanbul Üniversitesi Onkoloji Enstitüsü / Öğretim Üyesiacibadem.com.tr
- 2008 - 2010İstanbul Üniversitesi Onkoloji Enstitüsü / Yönetim Kurulu Üyesi - Araştırma ve Eğitimden Sorumlu Müdür Yardımcısıacibadem.com.tr
- 2004 - 2009İstanbul Üniversitesi Onkoloji Enstitüsü / İstanbul Üniversitesi İstanbul Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji BD / Tıbbi Onkoloji Doçentiacibadem.com.tr
- 2001 - 2002Dept. of Bioimmunotherapy Visiting Medical Oncologist:Dept of Breast Medical Oncology Univesity of Tesax, M.D. Anderson Cancer Center ,Houston,Texas / Postdoctoral Fellowacibadem.com.tr
- 2001 - 2004İstanbul Üniversitesi Onkoloji Enstitüsü / Tıbbi Onkoloji Uzmanıacibadem.com.tr
Formation
- 2001İstanbul Üniversitesi İstanbul Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
- 1997İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
- 1991İstanbul Üniversitesi İstanbul Tıp Fakültesi, Üniversiteacibadem.com.tr
Confiance
D’où viennent ces informations ?
La source est indiquée à côté de chaque information. Si vous constatez une erreur, vous pouvez suggérer une correction.
- SpécialitéOncologie médicaleacibadem.com.trD’après la source
- ÉtablissementAcıbadem Maslak Hastanesiacibadem.com.trD’après la source
- Sujet de travailTumeurs du seinDéduit de 25 publications · Version du modèle —D’après la source
- Publications193 publicationsOpenAlex, ORCIDD’après la source
- ORCID0000-0001-9603-4755ORCIDD’après la source
- Dernière synchronisation4 novembre 2026 20:47https://www.acibadem.com.tr/doktor/yesim-eralp/acibadem.com.tr
Travaux scientifiques
Publications sur Tumeurs du sein
-
Abstract PS4-11-08: Clinical characteristics and prognosis in interval detected breast cancer patients: a single institution cohort analysis
Clinical Cancer Research, 2026
DOI 10.1158/1557-3265.sabcs25-ps4-11-08 Source : OpenAlex
-
Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 1: Locoregional Therapy, Pathology, Radiology
European Journal of Breast Health, 2026
DOI 10.4274/ejbh.galenos.2026.2025-10-1 PMID 41873792 Texte intégral en libre accèsSource : OpenAlex
-
Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey
Scientific Reports, 2026
DOI 10.1038/s41598-026-61177-3 PMID 42414499 Texte intégral en libre accèsSource : OpenAlex
-
Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions
European Journal of Cancer Care, 2026
DOI 10.48130/ejcc-0026-0010 Source : OpenAlex
-
DNA Methylation Signatures Distinguish Breast Cancer Histological Subtypes and Predict Hormone Receptor Status: A TCGA-Based Integrative Analysis
Experimed, 2026
DOI 10.26650/experimed.1930098 Texte intégral en libre accèsSource : ORCID
-
Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment
European Journal of Breast Health, 2025
DOI 10.4274/ejbh.galenos.2025.2025-10-2 PMID 41447641 Texte intégral en libre accèsSource : OpenAlex
-
42P Concordance of CanAssist breast with Oncotype Dx and MammaPrint in patients with early stage hormone receptor positive breast cancer
ESMO Open, 2025
DOI 10.1016/j.esmoop.2025.104596 Texte intégral en libre accèsSource : OpenAlex
-
Metastatic Mixed-Type Liposarcoma of the Popliteal Fossa: Multimodal Treatment
Springer eBooks, 2025
DOI 10.1007/978-3-031-77061-6_31 Source : ORCID
-
First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.
Journal of Clinical Oncology, 2025
DOI 10.1200/jco.2025.43.16_suppl.1069 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex
-
Abstract PS2-06: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression
Clinical Cancer Research, 2025
DOI 10.1158/1557-3265.sabcs24-ps2-06 1 citation (OpenAlex) Source : OpenAlex